SynAct Pharma AB (SYNACT.ST) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Sweden · ISIN SE0008241491
SynAct Pharma AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 SEK | 0.00 SEK |
| Gross profit | -617,000.00 SEK | 0.00 SEK |
| Operating income | -89.98 m SEK | -117.15 m SEK |
| EBIT | -89.98 m SEK | -117.15 m SEK |
| Net income | -82.40 m SEK | -110.83 m SEK |
| Diluted EPS – continuing operations | -2.08 SEK | -2.17 SEK |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
More stocks
- DY Power Corp (210540.KS)
- Coherus Oncology, Inc. (CHRS)
- Country Group Holdings Public Company Limited (CGH.BK)
- L&K Biomed Ltd. (156100.KQ)
- UNITED BANCORP INC /OH/ (UBCP)
- Dongyang E&P Inc (079960.KQ)
- International Integrated Systems, Inc. (6614.TW)
- Globe International Ltd (GLB.AX)
- Jetway Information Co Ltd (6161.TWO)
- KCC Engineering & Construction Co. Ltd (021320.KQ)
- HF Foods Group Inc. (HFFG)
- Sahacogen (Chonburi) Public Company Limited (SCG.BK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.